|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.19 SEK | +10.00% |
|
+31.28% | +2.90% |
| 05-22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Enorama Pharma AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 0.678 million compared to SEK 0.049 million a year ago. Revenue was SEK 0.619 million compared to SEK 0.275 million a year ago.
Net loss was SEK 10.05 million compared to SEK 10.9 million a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.90% | 12.32M | |
| +20.76% | 43.77B | |
| +28.00% | 22.83B | |
| +20.25% | 15.56B | |
| +18.82% | 14.34B | |
| +55.83% | 12.96B | |
| -0.05% | 6.79B | |
| -12.70% | 6.41B | |
| -8.87% | 5.73B | |
| +14.65% | 5.69B |
ENORAMA PHARMA AB 
